A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the efficacy and safety of subcutaneous lirentelimab (AK002) in adult subjects with
H-1 antihistamine refractory chronic spontaneous urticaria. Subjects who complete the
randomized, double-blind, placebo-controlled treatment period may have the option to enroll
in an open-label extension period and receive up to 6 doses of subcutaneous lirentelimab.